CN101978982A - Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury - Google Patents
Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury Download PDFInfo
- Publication number
- CN101978982A CN101978982A CN2010105491374A CN201010549137A CN101978982A CN 101978982 A CN101978982 A CN 101978982A CN 2010105491374 A CN2010105491374 A CN 2010105491374A CN 201010549137 A CN201010549137 A CN 201010549137A CN 101978982 A CN101978982 A CN 101978982A
- Authority
- CN
- China
- Prior art keywords
- panacis japonici
- rhizoma panacis
- extract
- ethanol
- dose group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses application of Japanese ginseng or extract thereof which serves as an active ingredient to preparation of a medicament for resisting gout and repairing hyperuricemic kidney injury. Researches show that the uric acid lowering effect of the Japanese ginseng or the extract thereof is mainly realized by repairing the hyperuricemic kidney injury and increasing the renal displacement of uric acid.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to the application in the medicine of preparation gout and/or reparation metabolic arthritis injury of kidney of Rhizoma Panacis Japonici or its extract.
Background technology
Gout (gout) be purine metabolic disturbance cause uricopoiesis increase with or urate excretion reduce caused a kind of metabolic disease.Its clinical characters is a hyperuricemia; Urate deposition causes the acute and chronic arthritis and the soft tissue injury that show effect repeatedly; Gouty injury of kidney due to the uric acid renal calculus.When serum uric acid value 〉=416umol/L (7.0mg/dl) then becomes hyperuricemia.And metabolic arthritis (high dose yperuricimia) mass formed by blood stasis is the prerequisite and the biochemical basis of gout, and gout is inevitable with hyperuricemia; But the prevalence of gout because the urate excretion amount strengthens in the urine, can reduce the generation of gout far below hyperuricemia; The gout patient, maximum complication is the metabolic arthritis injury of kidney, can repair the medicine of metabolic arthritis injury of kidney, can improve urate excretion amount in the urine effectively, can treat gout, or reduces the sickness rate of gout.
Protein content is closely related in primary gout sickness rate and the diet.The world is during fighting for the first time and for the second time, because food quality descends, the sickness rate of European gout obviously reduces.And when postwar dietary protein content enriched once again, its sickness rate returned to level prewar again.After the Japanese economy rapid development sixties, its national dietary protein content significantly raises, so that gout also becomes the more common disease of Japanese.The clinical report of domestic gout also increases year by year, especially since the eighties, has increased significantly.The rising of this worldwide gout sickness rate changes relevant with progress, human lives's improvement, the life style of society over more than 20 years undoubtedly.
The prerequisite of gout morbidity is a hyperuricemia.Under blood p high dose 7.4 situations, uric acid exists with uric acid sodium ion form in the blood, so hyperuricemia is the metabolic arthritis natremia.All clinical manifestations of gout are all separated out and are deposited on tissue by its sodium salt from super-saturated extracellular fluid and cause.The nephropathy of gout is due to the urate crystal.
Kidney solid lesion such as kidney inflammation, cardiovascular pathological changes, when hypertension causes renal insufficiency, glomerular filtration rate reduces can cause that serum uric acid content raises, the secretion of renal tubules compensatory increases thereupon, gastrointestinal also drains that compensatory increases.But when glomerular filtration rate be reduced to＜during 25ml/min, above-mentioned compensation is promptly ineffective.So the patient of uremia, serum uric acid obviously raises.When the disease of the main infringement of part renal tubules such as polycystic kidney, lead poisoning, its serum uric acid content raises, and then is mainly renal tubules and secretes due to the minimizing.In recent years research thinks that the renal excretion deficiency is the main reason that hyperuricemia takes place.
Chinese medicine and pharmacy thinks that gout belongs to Chinese medical ' arthralgia syndrome ' category, at all times all the name " gout ".Gout is different from arthromyodynias such as " arthralgia aggravated by cold ", " migratory arthralgia ", and its unique syndrome characteristics are arranged.The arthromyodynia class all waits exopathogen to close because of wind and cold is wet and mix extremely, attacks in an opponent's defence due to the meridians, and which is more important shows the indefinite or fixing characteristics of not moving of sore spot migration because of ailment said due to cold or exposure or cold-evil; Gout then with outer wind-engaging cold-damp relation work and with the diet delicious food and drink relevant, night pilosity, redness and swelling of joints severe pain, then stiff for a long time swollen deformity; Subcutaneous formation yellow-white, protuberance not of uniform size, little of Semen Sesami, big as ovum gallinaceum, soft from the beginning of matter, gradually hard as stone, very then ulceration one-tenth is fullyed recover from an illness, and the outflow of adularescent pastel is not prolongedly healed.Ancient medicine also has observation to the characteristics that are different from anemofrigid-damp arthralgia of gout.Put down in writing as " Elementary Medicine gout ": " curl up contraction, very then a health piece trace of brothers then for a long time." clear Lin Peiqin " Lei Zheng Zhi Cai " put down in writing the symptom of gout visually: " its hands bending, body polylith trace; It is swollen as taking off, gradually to breaking; Its pain is as pulling unable to flex and stretch the extremities.”
At present, gout still there is not the radical cure medicine.The purpose of Drug therapy: 1. stop the recurrence of acute attack and prophylaxis of acute arthritis as early as possible; 2. prevent and treat urate deposition in tissues such as joint, kidney; 3. prevent uric acid renal calculus; 4. treat complication such as hypertension, hyperlipemia, diabetes.
1. colchicine (colchicine) is still the quick specific medicine of present treatment gouty arthritis.The low dose of oral administration of general employing, but the oral diarrhoea that causes easily waits gastrointestinal reaction.The low dose of intravenous injection administration of employing is also arranged, and thinking side effect such as can avoiding diarrhoea, vomiting also have the scholar that this is dissented.Though colchicine is relief of symptoms rapidly, do not have the effect that reduces blood uric acid, and side effect is bigger, gastrointestinal reaction is strong, and liver, renal function and hemopoietic system are all had infringement, and the someone thinks still can be carcinogenic.
2. NSAID (non-steroidal anti-inflammatory drug) such as indomethacin, diclofenac also can cause serious adverse reaction, and as digestive tract hemorrhage, aplastic anemia, hepatic and renal function injure etc., side effect is bigger.
3. glucocorticoid can be alleviated acute attack rapidly, but " knock-on " phenomenon (recurrence increases the weight of) often occurs after the drug withdrawal, and can prolong the course of disease, therefore generally can only be in colchicine, employing when NSAID (non-steroidal anti-inflammatory drug) is invalid.
4. but take sodium bicarbonate at catabasis great quantity of water drinking and alkalized urine, make the urine pH value remain on 6.2～6.8, help urate calculus dissolving in the urinary tract.Can take sodium bicarbonate etc.
5. excretory medicine of uricosuric such as probenecid, benzbromarone (narcaricin) etc. have the renal tubules of prevention and heavily absorb uric acid, increase the effect that uric acid is discharged.But when patient's renal function went down, curative effect descended even is invalid, so should not adopt; Existing urate calculus forms and also should not adopt, otherwise can add injury of kidney.
6. it is allopurinol that the medicine that suppresses uricopoiesis represent medicine, and its mechanism of action is that the competitive inhibition xanthine oxidase makes the uricopoiesis minimizing.Can share and to heighten the effect of a treatment with uricosuric.Its main side effects is liver, renal function injury (as interstitial nephritis) and bone marrow depression etc.Think in the past to be applicable to the patient with gout that renal function goes down, but more deep to its serious toxic and side effects understanding in recent years, limited it in the paracmastic application of gout.
To sum up, modern medicine is to the treatment of hyperuricemia and gout, because all there is more serious toxic and side effects in used main medicine, so often there is bigger treatment contradiction in the clinical use, in the selection and use to medicine, different scholars often has different views, and is especially rather thorny to the bad patient's of gout companion renal function treatment, still lacks comparatively ideal medicine and Therapeutic Method at present.
Summary of the invention
The objective of the invention is to overcome above-mentioned weak point a kind of Rhizoma Panacis Japonici or its extract, particularly Rhizoma Panacis Japonici saponin v or the application of its panax japonicus total saponins in the medicine of preparation gout and/or reparation metabolic arthritis injury of kidney are provided.
Rhizoma Panacis Japonici is the Araliaceae Radix Ginseng, belongs to the dry root of herbaceos perennial Panax japonicus C.A.Mey., contains multiple saponin, volatile oil, saccharide and several amino acids.Former is a kind of famous and precious Chinese herbal medicine among the people, has now recorded in the Pharmacopoeia of the People's Republic of China similar Radix Ginseng of medicinal function and Radix Notoginseng.Rhizoma Panacis Japonici is born in by hillside limes marginis, dark and damp area or the rock ditch ravine, mainly is distributed in ground such as Guizhou, Hunan, Yunnan, Anhui, Jiangxi, Hubei.Excavate annual autumn, removes stem and leaf, tells fleshy tap root, and rhizome is removed crust, dries or dry in the shade and can be used as medicine.Beginning is stated from supplementary Amplifications of the Compendium of Materia Medica.Sweet, the little hardship of Rhizoma Panacis Japonici, temperature.Have multiple efficacies such as blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, strengthening by means of tonics, the strengthening by means of tonics effect of existing similar Radix Ginseng has eliminating stasis to stop pain, hemostasis, the phlegm-dispelling functions of similar Radix Notoginseng again, is mainly used in weakness, chronic cough hemoptysis, cough with copious phlegm, traumatic injury after being ill.
The present invention is achieved by the following technical solutions:
Rhizoma Panacis Japonici or Rhizoma Panacis Japonici extract are used in the medicine of preparation gout and/or reparation metabolic arthritis injury of kidney as active component.
Above-mentioned Rhizoma Panacis Japonici extract can be the refining Rhizoma Panacis Japonici extract that the water extract of water extract, ethanol extract, Rhizoma Panacis Japonici of Rhizoma Panacis Japonici or ethanol extract obtain after refining.Refining Rhizoma Panacis Japonici extract is preferably Rhizoma Panacis Japonici saponin v or panax japonicus total saponins.Wherein, the content of Rhizoma Panacis Japonici saponin v 〉=50% in the panax japonicus total saponins; The purity of described Rhizoma Panacis Japonici saponin v 〉=90%.
Above-mentioned ethanol extract is the extract of ethanol or methanol, and the weight percent concentration of ethanol or methanol is 10-90%, preferred concentration 50-70%.
The water extract of described Rhizoma Panacis Japonici can be prepared by following method: get the Rhizoma Panacis Japonici medical material, add the decocting that Rhizoma Panacis Japonici 6-12 doubly measures and boil 1-4 time, decocting time was respectively 1-3 hour, filtered, and merging filtrate concentrates, promptly.
The ethanol extract of described Rhizoma Panacis Japonici is prepared by following method: get the Rhizoma Panacis Japonici medical material, ethanol or methanol eddy that adding Rhizoma Panacis Japonici 6-12 doubly measures extracted 1-3 hour, filtered, and got filtrate; Ethanol that medicinal residues reuse 6-12 doubly measures or methanol eddy extract 1-3 time, and each 1-3 hour, filter, merging filtrate concentrates, promptly.
Described Rhizoma Panacis Japonici or Rhizoma Panacis Japonici extract, particularly Rhizoma Panacis Japonici saponin v or panax japonicus total saponins can become compositions with pharmaceutically acceptable preparing carriers as active component.
Above-mentioned pharmaceutically acceptable carrier comprises the adjuvant of oral formulations adjuvant or parenteral administration.Route of administration can be oral, injection, topical etc.According to technical scheme of the present invention, said composition can be oral formulations or injection preparation, and wherein oral formulations comprises capsule, soft capsule, granule, oral liquid, tablet, drop pill etc.Used adjuvant comprises: conventional adjuvants such as starch, sucrose, lactose, Icing Sugar, glucose, mannitol, xylitol, Polyethylene Glycol, isopropyl alcohol, tween 80, glycerol, propylene glycol, microcrystalline Cellulose sodium, dextrin, cyclodextrin, sodium chloride, vitamin C, cysteine, citric acid, sodium thiosulfate, sodium sulfite, stearate and gelatin, preparation later stage preparation technology and equipment all belong to the routine techniques of pharmaceutical field, the present invention does not limit this, so will not describe in detail at this.
The dosage of above-mentioned composition oral administration is 2-3 time/day, and the dosage of at every turn amounting to into Rhizoma Panacis Japonici saponin v or panax japonicus total saponins is respectively 0.125～0.25g/ time and 0.25～0.50g/ time.
Rhizoma Panacis Japonici is the Chinese herbal medicine of using always, and secular traditional Chinese medical science medication experience is arranged, and this medicine is safe to use, no overt toxicity effect record.Rhizoma Panacis Japonici saponin v of the present invention or panax japonicus total saponins are to extract to obtain from natural Chinese medicine Rhizoma Panacis Japonici, effect experiment shows Rhizoma Panacis Japonici or Rhizoma Panacis Japonici extract, particularly Rhizoma Panacis Japonici saponin v or panax japonicus total saponins have the utmost point significance effect that reduces animal pattern serum uric acid content, also have the utmost point significance effect of repairing the injury of kidney that hyperuricemia causes simultaneously.
Beneficial effect of the present invention compared with the prior art: present anti-gout drugs is mainly the purine oxidase inhibitor, this research shows that first Rhizoma Panacis Japonici or its extract, particularly panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, Rhizoma Panacis Japonici alcohol extract, Rhizoma Panacis Japonici crude drug have the pharmacologically active of uric acid resisting gout and repair the activity of metabolic arthritis injury of kidney.The uric acid resisting effect that studies show that Rhizoma Panacis Japonici or its extract mainly is to realize by the kidney discharge capacity of repairing metabolic arthritis injury of kidney, increase uric acid, therefore, Rhizoma Panacis Japonici or its extract have the prospect that is developed to gout and/or repairs the medicine of metabolic arthritis injury of kidney.
The specific embodiment
Embodiment 1
The preparation of Rhizoma Panacis Japonici saponin v, panax japonicus total saponins
The preparation of panax japonicus total saponins: get Rhizoma Panacis Japonici coarse granule 200 gram, place the round-bottomed flask of 3000ml, add 60% ethanol of 10 times of amounts of Rhizoma Panacis Japonici coarse powder, soaked 2 hours, water-bath reflux, extract, 2 hours filters, must filtrate.60% alcohol reflux of 10 times of amounts of medicinal residues reuse 2 times each 2 hours, filters.Merge 3 times filtrate, decompression recycling ethanol is to there not being the alcohol flavor, be mixed with medical material: medicinal liquid (g/ml) is 0.5: 1 a aqueous solution, on the HPD-100 macroporous resin column handled well, water, 60% ethanol elution discard water elution liquid successively, merge 60% ethanol elution, reclaim solvent and do,, obtain about 15 grams of panax japonicus total saponins through 65 ℃ of drying under reduced pressure near.
The preparation of Rhizoma Panacis Japonici saponin v: get the Rhizoma Panacis Japonici coarse powder, add 60% ethanol of 10 times of amounts of Rhizoma Panacis Japonici coarse powder, soaked 2 hours, water-bath reflux, extract, 2 hours filters, must filtrate.60% alcohol reflux of 10 times of amounts of medicinal residues reuse 2 times each 2 hours, filters.Merge 3 times filtrate, decompression recycling ethanol is not to there being the alcohol flavor, and be mixed with medical material: medicinal liquid (g/ml) is 0.5: 1 a solution.On the HPD-100 macroporous resin column handled well, water, 60% ethanol elution successively.Merge 60% ethanol elution, reclaim solvent and do,, obtain panax japonicus total saponins through 65 ℃ of drying under reduced pressure near.Panax japonicus total saponins is collected the ethanol elution of 50%-90% again through ADS-7 macroporous resin column purification, decompression recycling ethanol, and drying under reduced pressure gets Rhizoma Panacis Japonici saponin V, and its purity is greater than 90%.
Embodiment 2
The assay of Rhizoma Panacis Japonici saponin v and panax japonicus total saponins thereof
1. chromatographic condition
SPD-20A high performance liquid chromatograph, chromatographic column are Boston analytics, Green ODS-AQ 4.6 * 150mm 5um, wavelength is 203nm, and sample size is 20ul, and flow velocity is 1.0ml/min, column temperature is 25 ℃, and mobile phase is acetonitrile (A): 10mM phosphoric acid buffer aqueous solution (B) (takes by weighing KH
2PO
4Medicine 0.68g adds the 500ml pure water, uses K
2HPO
4Adjust pH to 5.8, mixing, through the filtering with microporous membrane of 0.45um, ultrasonic 10-15 minute is promptly) gradient elution (gradient of eluting is: 0-19 minute, and A: B=27: 73; 20-33 minute, A: B=28: 72; 34-43 minute, A: B=34: 66; 44-57 minute, A: B=43: 57; 57.5-64 minute, A: B=85: 15; 65-80 minute, A: B=27: 73).
2. the preparation of reference substance Rhizoma Panacis Japonici saponin v (also claim the ginsenoside Ro, can be called for short Ro) solution: it is an amount of to get Rhizoma Panacis Japonici saponin v, is mixed with reference substance solution with water, and its concentration is 1.45mg/ml.
3. the preparation of Rhizoma Panacis Japonici saponin v and panax japonicus total saponins sample liquid thereof:
The panax japonicus total saponins sample 23.71mg that takes by weighing, fixed molten with water is 25ml, is the panax japonicus total saponins sample liquid.
The Rhizoma Panacis Japonici saponin v sample 12.00mg that takes by weighing, fixed molten with water is 25ml, is Rhizoma Panacis Japonici saponin v sample liquid.
4. the assay of Rhizoma Panacis Japonici saponin v and panax japonicus total saponins sample thereof:
Essence is got above-mentioned panax japonicus total saponins sample liquid, Rhizoma Panacis Japonici saponin v sample liquid and each 20ul of reference substance solution respectively, inject chromatographic column, measure by above-mentioned chromatographic condition, the reference substance Ro peak area that records is 5750034.5, the Ro peak area is 1962145.125 in the panax japonicus total saponins sample that records, the Ro peak area is 1758717.5 in the Rhizoma Panacis Japonici saponin v sample that records
The concentration of Ro in the panax japonicus total saponins sample that calculates, C
The panax japonicus total saponins sample=C
Reference substance* S
The panax japonicus total saponins sample/ S
Reference substance=1.45 * 1962145.125/5750034.5=0.495mg/ml.Calculate the percentage composition of Ro in the panax japonicus total saponins sample, be C
The panax japonicus total saponins sample* V
The panax japonicus total saponins sample/ W
The panax japonicus total saponins sample=0.495mg/ml * 25ml/23.71mg=52.2%.
The concentration of Ro in the Rhizoma Panacis Japonici saponin v sample that calculates, C
Rhizoma Panacis Japonici saponin v sample=C
Reference substance* S
Rhizoma Panacis Japonici saponin v sample/ S
Reference substance=1.45 * 1758717.5/5750034.5=0.4435mg/ml.Calculate the percentage composition of Ro in the Rhizoma Panacis Japonici saponin v sample, be C
Rhizoma Panacis Japonici saponin v sample* V
Rhizoma Panacis Japonici saponin v sample/ W
Rhizoma Panacis Japonici saponin v sample=0.4435mg/ml * 25ml/12.00mg=92.4%.
Embodiment 3
The experimentation of panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, Rhizoma Panacis Japonici ethanol extraction, Rhizoma Panacis Japonici methanolic extract and Rhizoma Panacis Japonici medicinal powder gout
1. experiment material: TONGFENGDING capsule (Chengdu Zhong Jiang pharmaceutical Co. Ltd lot number 090104), (bio tech ltd is built up in Nanjing to Oteracil Potassium, lot number: 090204), xanthine (sigma), (bio tech ltd is built up in Nanjing to the testing uric acid test kit, lot number 20090420), (bio tech ltd is built up in Nanjing to the Coomassie brilliant blue protein determination kit, lot number 20090325) (bio tech ltd is built up in Nanjing to xanthine oxidase mensuration test kit, lot number 20090514), ebutol (Hangzhou Minsheng Pharmaceutical Group Co, lot number T09L542), (bio tech ltd is built up in Nanjing to the testing uric acid test kit, lot number 20091120), creatinine assay test kit (biological study institute, lot number 20091006 are built up in Nanjing), blood urea nitrogen testing cassete (biological study institute, lot number 20101113 are built up in Nanjing).Adenine (the auspicious new Pharmaceutical in Zhejiang limited company, lot number: 091105), Rhizoma Panacis Japonici medical material (through being accredited as the dry root of Araliaceae Panax Rhizoma Panacis Japonici Panax japonicus C.A.Mey); Panax japonicus total saponins (preparing) according to embodiment 1 method.
2. various preparations for reagent liquid
The preparation of positive control drug TONGFENGDING solution: precision takes by weighing 1.8720 gram TONGFENGDING powder, be dissolved in 60 milliliter 0.5% the CMC-Na solution, the concentration that gets medicinal liquid is the 31.2mg/mlCMC-Na aqueous solution, and the administration volume of mice is 0.2ml/10g, and the mice dosage is: 0.624g/kg.
The preparation of panax japonicus total saponins high dose solution: precision takes by weighing 0.3750 gram panax japonicus total saponins powder dissolution in 25 milliliters 0.5% CMC-Na solution, and promptly getting concentration is the panax japonicus total saponins solution of 15mg/ml, and dosage is 0.3g/kg;
The preparation of panax japonicus total saponins low dosage solution: precision takes by weighing 0.1250 gram panax japonicus total saponins powder dissolution in 25 milliliters 0.5% CMC-Na solution, and promptly getting concentration is the panax japonicus total saponins solution of 5mg/ml, and dosage is 0.1g/kg.
The preparation of Rhizoma Panacis Japonici saponin v high dose solution: precision takes by weighing 0.1875 gram Rhizoma Panacis Japonici saponin v powder dissolution in 25 milliliters 0.5% CMC-Na solution, and promptly getting concentration is the Rhizoma Panacis Japonici saponin v solution of 7.5mg/ml, and dosage is 0.15g/kg;
The preparation of Rhizoma Panacis Japonici saponin v low dosage solution: precision takes by weighing 0.0625 gram Rhizoma Panacis Japonici saponin v powder dissolution in 25 milliliters 0.5% CMC-Na solution, and promptly getting concentration is the Rhizoma Panacis Japonici saponin v solution of 2.5mg/ml, and dosage is 0.05g/kg.
The preparation of Rhizoma Panacis Japonici water extract high dose solution: get Rhizoma Panacis Japonici coarse granule 200g, the straight fire of water that adds 10 times of amounts decocts 3 times, and decocting time was respectively 1.5 hours, 1 hour and 1 hour.Filter, merge 3 times extracting solution, it is 0.1g crude drug/ml that water-bath is concentrated into liquor strength, and dosage is 2g crude drug/kg.
The preparation of Rhizoma Panacis Japonici water extract low dosage solution: get Rhizoma Panacis Japonici coarse granule 3.5g, the straight fire of water that adds 10 times of amounts decocts 3 times, and decocting time was respectively 1.5 hours, 1 hour and 1 hour.Filter, merge 3 times extracting solution, water-bath is concentrated into 0.035g crude drug/ml, and dosage is 0.7g crude drug/kg.
The preparation of Rhizoma Panacis Japonici ethanol extract high dose solution: get the Rhizoma Panacis Japonici coarse granule by embodiment 1 " preparation of panax japonicus total saponins " method, place round-bottomed flask, add 60% ethanol of 10 times of amounts of Rhizoma Panacis Japonici coarse powder, soaked 2 hours, water-bath reflux, extract, 2 hours filters, and gets filtrate.60% alcohol reflux of 10 times of amounts of medicinal residues reuse 2 times each 2 hours, filters.Merge 3 times filtrate, decompression recycling ethanol is not to there being the alcohol flavor, and it is 0.1g crude drug/ml that water-bath is concentrated into liquor strength, and dosage is 2g crude drug/kg.
The preparation of Rhizoma Panacis Japonici ethanol extract low dosage solution: extract and recovery ethanol according to " preparation of Rhizoma Panacis Japonici ethanol extract high dose solution " method, water-bath is concentrated into 0.035g crude drug/ml, and dosage is 0.7g crude drug/kg.
The preparation of Rhizoma Panacis Japonici medicinal powder high dose solution: Rhizoma Panacis Japonici is ground into 100 order powder, and the CMC-Na solution suspendible with 0.5% is prepared into the suspension of 0.1g crude drug/ml.Dosage is 2g crude drug/kg.
The preparation of Rhizoma Panacis Japonici medicinal powder low dosage solution: Rhizoma Panacis Japonici is ground into 100 order powder, and the CMC-Na solution suspendible with 0.5% is prepared into the suspension of 0.035g crude drug/ml.Dosage is 0.7g crude drug/kg.
The preparation of Rhizoma Panacis Japonici methanol extract liquid high dose solution: extract and reclaim methanol (soon ethanol replaces with methanol in this method) according to " preparation of Rhizoma Panacis Japonici ethanol extract high dose solution " method, be mixed with the aqueous solution that concentration is 0.1g crude drug/ml, dosage is 2g crude drug/kg.
The preparation of Rhizoma Panacis Japonici methanol extract liquid low dosage solution: extract and reclaim ethanol (soon ethanol replaces with methanol in this method) according to " preparation of Rhizoma Panacis Japonici ethanol extract high dose solution " method, be concentrated into 0.035g crude drug/ml, dosage is 0.7g crude drug/kg.
The preparation of modeling agent: precision takes by weighing Oteracil Potassium 0.3012 gram, xanthine 0.1753 gram, is dissolved in 40 milliliter 0.5% the solution of CMC-Na.The dosage of Oteracil Potassium is 150.6mg/kg, and administration concentration is 7.53mg/ml; Xanthic dosage is 87.7mg/kg, and administration concentration is 4.383mg/ml.
0.5% CMC-Na solution preparation: take by weighing CMC-Na 2.5 grams and add ultrasonic its dissolving, the standing over night of making of heating in 500 milliliters of pure water.
The preparation of normal saline: take by weighing 4.5041 gram sodium chloride, be dissolved in 500 milliliters of pure water promptly.
The preparation of modeling agent: (vitamin B4 tablet (adenine) and ebutol sheet mixed solution): take by weighing adenine 1.040 grams and ebutol 1.500 grams, with its ultrasonic dissolution in 60 milliliters CMC-Na solution promptly, the concentration of adenine, ebutol is respectively 17.33mg/ml, 25mg/ml.The filling body of stomach of modeling amasss 0.2ml/10g, and the adenine dosage is 346mg/kg, and the ebutol dosage is 500mg/kg.
3. metabolic arthritis mouse model gout experimentation
1) experimental technique: get 150 of Male Kunming strain mice, body weight 18-22g is divided into 15 groups at random, 10 every group.Be respectively blank group, the blank group of model, positive control drug TONGFENGDING Capsules group, the panax japonicus total saponins high dose group, the panax japonicus total saponins low dose group, Rhizoma Panacis Japonici saponin v high dose group, Rhizoma Panacis Japonici saponin v low dose group, Rhizoma Panacis Japonici water extract high dose group, Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract high dose group, Rhizoma Panacis Japonici ethanol extract low dose group, Rhizoma Panacis Japonici medicinal powder high dose group, Rhizoma Panacis Japonici medicinal powder low dose group, Rhizoma Panacis Japonici methanol extract liquid high dose group, Rhizoma Panacis Japonici methanol extract liquid low dose group.Each group mice is carried out gastric infusion, administration 3 days.The blank group of blank group and model gives the CMC-Na solution of equal-volume (0.2ml/10g) 0.5% respectively; All the other each administration groups give relative medicine by the 0.2ml/10g volume respectively, and their dosage is respectively: TONGFENGDING group 0.624g TONGFENGDING/kg, panax japonicus total saponins high dose group 0.3g panax japonicus total saponins/kg, panax japonicus total saponins low dose group 0.1g panax japonicus total saponins/kg, Rhizoma Panacis Japonici saponin v high dose group 0.15g Rhizoma Panacis Japonici saponin v/kg, Rhizoma Panacis Japonici saponin v low dose group 0.05g Rhizoma Panacis Japonici saponin v/kg, Rhizoma Panacis Japonici water extract high dose group 2g crude drug/kg, Rhizoma Panacis Japonici water extract low dose group 0.7g crude drug/kg, Rhizoma Panacis Japonici ethanol extract high dose group 2g crude drug/kg, Rhizoma Panacis Japonici ethanol extract low dose group 0.7g crude drug/kg, Rhizoma Panacis Japonici medicinal powder high dose group 2g crude drug/kg, Rhizoma Panacis Japonici medicinal powder low dose group 0.7g crude drug/kg, Rhizoma Panacis Japonici methanol extract liquid high dose group 2g crude drug/kg, Rhizoma Panacis Japonici methanol extract liquid low dose group 0.7g crude drug/kg.In the last administration preceding 1 hour, except that the blank group, other respectively organize equal lumbar injection 0.2ml/10g xanthine (concentration is 4.383mg/ml) and Oteracil Potassium (concentration is 7.53mg/ml) modeling, and the dosage of modeling is: xanthine is that 87.7mg/kg, Oteracil Potassium are 150.6mg/kg.After the modeling each group mice put into the urine uric acid to be determined that corresponding metabolic cage was collected after the modeling 1 hour; After 1 hour each group mice is carried out gastric infusion in modeling; Collect the urine uric acid to be determined in 1 hour after the administration; After the administration 1 hour, each group mice is plucked that eyeball is got blood and liver organization is won in dissection, the activity of xanthine oxidase in the content regulating liver-QI tissue fluid of uric acid in the test serum.Adopt xanthine oxidase test kit and uric acid reagent box to measure the content of uric acid in the activity of xanthine oxidase in the mouse liver and serum and the urine respectively.
(1) testing sample is handled and is measured
The processing of blood sample: each group mice is plucked eyeball get blood, separation of serum (4000rp/ per minute, centrifugal 15 minutes), the serum that separation is obtained place-20 ℃ of refrigerators to preserve test serum uric acid (UA).
The processing of hepatic tissue: the hepatic tissue of getting each mice, immediately with taking by weighing on the electronic balance about 0.05g, place the centrifuge tube of 2ml, the normal saline that adds 9 times of amounts, grind homogenate 1 minute with refiner 10000r/min, each part homogenate is carried out centrifugal (4000r/min), centrifugal 10 minutes, the activity and the Tot Prot thereof of absorption supernatant 40 microlitres xanthine oxidase to be measured.
The processing of urine: there are 10 animals in each experiment group, respectively per 2 are placed in the same metabolic cage simultaneously and collect urine, each experiment group each gets 5 parts of experiment urines, and each part mice urine is added the dilution of 9 times of amount normal saline respectively, gets the urine sample liquid to be measured of each part.
(2) mensuration of various experimental index
The method of test kit, Coomassie brilliant blue protein determination kit of measuring according to testing uric acid test kit, xanthine oxidase is measured.Calculate uric acid content (umol/L), hepatic tissue xanthine oxidase (XOD) active (U/gprot) and protein content (g/L) with following computing formula.
Uric acid content (umol/L)=standard pipe uric acid content * mensuration pipe absorbance/standard pipe absorbance.Standard pipe uric acid content 297.4umol/l.
XOD activity (U/gprot)=N * (A sample-A sky)/C * T * Cprot * 0.0126.N: reaction system extension rate (23.7; A sample: the absorbance of sample determination pipe; A sky: the absorbance of blank determination pipe; C: colorimetric optical path (1cm); Cprot: protein content in the sample to be tested (gprot/L); T: response time (20 minutes); XOD: xanthine oxidase.
Protein content (g/L)=standard pipe protein concentration * (measuring pipe OD value-blank pipe OD value)/(standard pipe OD value-blank pipe OD value).The protein concentration of standard pipe is: 0.563g/L.
(3) experimental result and analysis
The gained data are carried out statistical analysis with the SPSS11.5 statistical analysis software, and the result sees table 1-3 for details.
Table 1: each organizes the exercising result (n=10) of medicine to the mice serum uric acid level
Annotate: compare with the blank group,
△P＜0.05,
△ △P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01.
Table 2: each organizes the exercising result (n=10) of medicine to the mouse liver xanthine oxidase activity
Annotate: compare with the blank group,
△P＜0.05,
△ △P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01.
Table 3: each group is to the exercising result (n=10) of mice urine urate excretion amount
Annotate: compare with the blank group,
△P＜0.05,
△ △P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01; Compare with positive controls
▲P＜0.05,
▲ ▲P＜0.01.
Analyze conclusion:
(1). by analyzing mice serum uric acid index, model group compares with blank group, has utmost point significant difference (P＜0.01), shows hyperuricemia model modeling success; Panax japonicus total saponins high dose group, panax japonicus total saponins low dose group, Rhizoma Panacis Japonici saponin v high dose group, Rhizoma Panacis Japonici saponin v low dose group, Rhizoma Panacis Japonici water extract high dose group, Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract high dose group, Rhizoma Panacis Japonici ethanol extract low dose group, Rhizoma Panacis Japonici methanol extract high dose group, Rhizoma Panacis Japonici methanol extract low dose group, Rhizoma Panacis Japonici medicinal powder high dose group, Rhizoma Panacis Japonici medicinal powder low dose group and model group relatively have utmost point significant difference (P＜0.01), and the TONGFENGDING group has significant difference (P＜0.05).Show that Rhizoma Panacis Japonici crude drug, panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, Rhizoma Panacis Japonici alcohol extract all have the effect that serum uric acid falls in significance, their action intensity is better than the TONGFENGDING group.
(2). by analyzing the activity of mouse liver xanthine oxidase, the panax japonicus total saponins high dose group, the panax japonicus total saponins low dose group, Rhizoma Panacis Japonici saponin v high dose group, Rhizoma Panacis Japonici saponin v low dose group, Rhizoma Panacis Japonici water extract high dose group, Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract high dose group, Rhizoma Panacis Japonici ethanol extract low dose group, Rhizoma Panacis Japonici methanol extract high dose group, Rhizoma Panacis Japonici methanol extract low dose group, Rhizoma Panacis Japonici medicinal powder high dose group, Rhizoma Panacis Japonici medicinal powder low dose group and model group relatively have utmost point significant difference (P＜0.01), and TONGFENGDING group and model group relatively have significant difference (P＜0.05).Show that Rhizoma Panacis Japonici crude drug, panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, Rhizoma Panacis Japonici alcohol extract have the effect that utmost point significance suppresses xanthine oxidase activity, TONGFENGDING has the active function that significance suppresses xanthine oxidase, and their action intensity is better than the TONGFENGDING group.
(3). by analyzing mice urine urate excretion total amount, the panax japonicus total saponins high dose group, the panax japonicus total saponins low dose group, Rhizoma Panacis Japonici saponin v high dose group, Rhizoma Panacis Japonici saponin v low dose group, Rhizoma Panacis Japonici water extract high dose group, Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract high dose group, Rhizoma Panacis Japonici ethanol extract low dose group, Rhizoma Panacis Japonici methanol extract high dose group, Rhizoma Panacis Japonici methanol extract low dose group, Rhizoma Panacis Japonici medicinal powder high dose group, Rhizoma Panacis Japonici medicinal powder low dose group and model group more all have utmost point significant difference (P＜0.01), TONGFENGDING group and model group relatively have significant difference (P＜0.05), show the panax japonicus total saponins low dose group, the panax japonicus total saponins high dose group, the TONGFENGDING group all has the effect that promotes the urine urate excretion.The panax japonicus total saponins high dose group, the panax japonicus total saponins low dose group, Rhizoma Panacis Japonici saponin v high dose group, Rhizoma Panacis Japonici saponin v low dose group, Rhizoma Panacis Japonici water extract high dose group, Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract high dose group, Rhizoma Panacis Japonici ethanol extract low dose group, Rhizoma Panacis Japonici methanol extract high dose group, Rhizoma Panacis Japonici methanol extract low dose group, Rhizoma Panacis Japonici medicinal powder high dose group, Rhizoma Panacis Japonici medicinal powder low dose group and TONGFENGDING group are relatively, the effect of this promotion urine urate excretion, exist utmost point significant difference (P＜0.01) between them, show panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, the Rhizoma Panacis Japonici alcohol extract has the advantage of the utmost point significance that promotes the urine urate excretion.
Brief summary: show that Rhizoma Panacis Japonici crude drug, panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, Rhizoma Panacis Japonici alcohol extract by suppressing the activity of liver xanthine oxidase, promote the drainage of urine uric acid, and serum uric acid value utmost point significance is reduced.The gout effect that shows Rhizoma Panacis Japonici crude drug, panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, Rhizoma Panacis Japonici alcohol extract obviously is better than the positive control drug TONGFENGDING.
Embodiment 4
Panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, Rhizoma Panacis Japonici ethanol extraction are repaired the metabolic arthritis experimental study of renal damage, and the preparation of experiment material and sample is with embodiment 3.
Repair metabolic arthritis model mice renal failure experimentation
(1). experimental technique: get 132 Male Kunming strain mice, body weight is 20-22g, is divided into 11 groups at random, every group each 12.Be respectively blank group, the blank group of model, positive control drug TONGFENGDING Capsules group, panax japonicus total saponins high dose group, panax japonicus total saponins low dose group, Rhizoma Panacis Japonici saponin v high dose group, Rhizoma Panacis Japonici saponin v low dose group, Rhizoma Panacis Japonici water extract high dose group, Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract high dose group, Rhizoma Panacis Japonici ethanol extract low dose group.Each group mice label is weighed, and every morning 8:30 begins each group mice irritated respectively and gives the modeling agent.Modeling method adopts mouse stomach adenine and ebutol to set up the gouty renal injury model, the volume that stomach is irritated in modeling is 0.2ml/kg, modeling dosage is: adenine 346mg/kg (concentration is 17.33mg/ml), ebutol 500mg/kg (concentration is 25mg/ml).Modeling is 21 days continuously, and modeling and administration are carried out simultaneously.Evening, 20:30 began corresponding medicine is given in each group mice filling, and the blank group of blank group and model gives the CMC-Na solution of equal-volume (0.2ml/10g) 0.5% respectively; All the other each administration groups give relative medicine by the 0.2ml/10g volume respectively, and their dosage is respectively: TONGFENGDING group 0.624g TONGFENGDING/kg, panax japonicus total saponins high dose group 0.3g panax japonicus total saponins/kg, panax japonicus total saponins low dose group 0.1g panax japonicus total saponins/kg, Rhizoma Panacis Japonici saponin v high dose group 0.15g Rhizoma Panacis Japonici saponin v/kg, Rhizoma Panacis Japonici saponin v low dose group 0.05g Rhizoma Panacis Japonici saponin v/kg, Rhizoma Panacis Japonici water extract high dose group 2g crude drug/kg, Rhizoma Panacis Japonici water extract low dose group 0.7g crude drug/kg, Rhizoma Panacis Japonici ethanol extract high dose group 2g crude drug/kg, Rhizoma Panacis Japonici ethanol extract low dose group 0.7g crude drug/kg.Claimed its weight every 7 days to each group mice, redefine the modeling of each group and the filling body of stomach of administration and amass.At the 7th day, the 14th day, the 21st day that tests each group mice is carried out eye socket and get blood, separation of serum (4000rp per minute, centrifugal 15 minutes), the serum that separation is obtained places-20 ℃ of refrigerators to preserve test serum uric acid (UA), serum urea nitrogen (BUN), 3 indexs of serum creatinine (SCr).The experimental result that compares three testing indexs, thus analyze and estimate of the repair of each administration group to injury of kidney.
The modeling mechanism of gouty injury of kidney: the high concentration adenine is insoluble in 2 of water by the effect generation utmost point of xanthine oxidase; 8-dihydroxy adenine; 2; 8-dihydroxy adenine is deposited on renal tubules; influenced the drainage of nitrogen materialization compound, caused azotemia, toxin to be accumulated and electrolyte and disorder of amino acid metabolism, ebutol suppresses renal tubules to the uric acid excretion; make the urate excretion minimizing and cause hyperuricemia, thereby cause the chronic nephritis and the renal failure of metabolic arthritis.
(2). the determination experiment pointer operation
Method according to uric acid reagent box, creatinine reagent box, blood urea nitrogen test kit is measured.
Computing formula:
Serum uric acid (umol/l)=standard pipe content * mensuration pipe absorbance/standard pipe absorbance.Standard pipe uric acid content 297.4umol/l
Serum creatinine (umol/L)=standard pipe concentration * 11
** (A measures the blank pipe of pipe-A)/(the blank pipe of A standard pipe-A).Standard pipe concentration 10umol/L wherein.
Urea nitrogen content (mmol/l)=concentration of standard solution * (A measures the blank pipe of pipe-A)/(the blank pipe of A standard pipe-A).Concentration of standard solution 10mmol/L.
(3). experimental result
Excel table 2 is seen in the record of initial data and calculating.Gained data SPSS11.5 statistical analysis, experimental result are represented with x ± SD, see table 4-6 for details.
Table 4: serum uric acid value (umol/l)
Annotate: compare with the blank group,
*P＜0.05,
*P＜0.01; Compare with model group,
△P＜0.05,
△ △P＜0.01.
Table 5: serum urea nitrogen (mmol/l)
Annotate: compare with the blank group,
*P＜0.05,
*P＜0.01; Compare △ P＜0.05, △ △ P＜0.01 with model group.
Table 6: serum creatinine (umol/L)
Annotate: compare with the blank group,
*P＜0.05,
*P＜0.01; Compare △ P＜0.05, △ △ P＜0.01 with model group.
(4). analyze and sum up
1. model group compares with blank group, all have utmost point significant difference (P＜0.01) in modeling after 7 days, modeling after 14 days, modeling three indexs of serum uric acid value, blood urea nitrogen, serum creatinine value after 21 days, show and irritate the renal injury model modeling success that mice persistence hyperuricemia that gastric gland purine and ebutol cause causes.
2. by analyzing of the influence of positive control drug TONGFENGDING to serum urea nitrogen value, serum creatinine value; show in the renal injury model that the mice persistence hyperuricemia that adenine and ebutol cause causes; Chinese medicine positive control drug TONGFENGDING capsule, the injury of kidney that metabolic arthritis is caused does not have protective effect.
3. by serum analysis uric acid level index, after the 7th, 14 days, panax japonicus total saponins high dose group, panax japonicus total saponins low dose group, Rhizoma Panacis Japonici saponin v high dose group, Rhizoma Panacis Japonici saponin v low dose group, Rhizoma Panacis Japonici water extract high dose group, Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract high dose group, Rhizoma Panacis Japonici ethanol extract low dose group and model group more all have the difference of utmost point significance (P＜0.01) in modeling; After the 21st day, panax japonicus total saponins low dose group, Rhizoma Panacis Japonici saponin v low dose group, Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract low dose group and model group have significant difference (P＜0.05) more respectively and panax japonicus total saponins high dose group, Rhizoma Panacis Japonici saponin v high dose group, Rhizoma Panacis Japonici water extract high dose group, Rhizoma Panacis Japonici ethanol extract high dose group have utmost point significant difference (P＜0.01) in modeling; Chinese medicine positive drug TONGFENGDING Capsules group and model group relatively only have the difference of utmost point significance (P＜0.01) after the 7th day in modeling.Show that panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, the uric acid resisting effect of Rhizoma Panacis Japonici ethanol extract in the renal injury model that hyperuricemia causes obviously are better than Chinese medicine positive drug TONGFENGDING capsule.
4. by serum analysis blood urea nitrogen index, after the 7th day, after 14 days, panax japonicus total saponins high dose group, panax japonicus total saponins low dose group, Rhizoma Panacis Japonici saponin v high dose group, Rhizoma Panacis Japonici saponin v low dose group, Rhizoma Panacis Japonici water extract high dose group, Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract high dose group, Rhizoma Panacis Japonici ethanol extract low dose group and model group more all have utmost point significant difference (P＜0.01) in modeling; Behind modeling administration table the 21, only Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract low dose group have significant difference (P＜0.05), and other administration group all has utmost point significant difference (P＜0.01); And Chinese medicine positive drug TONGFENGDING Capsules group and model group are relatively, only have the difference of utmost point significance (P＜0.01) after the 7th day in modeling.Panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, the Rhizoma Panacis Japonici ethanol extract reparation injury of kidney effect in the renal injury model that hyperuricemia causes that shows obviously is better than Chinese medicine positive drug TONGFENGDING capsule.
5. by serum analysis creatinine index, in modeling after the 7th day, panax japonicus total saponins high dose group, panax japonicus total saponins low dose group, Rhizoma Panacis Japonici saponin v high dose group, Rhizoma Panacis Japonici saponin v low dose group, Rhizoma Panacis Japonici water extract high dose group, Rhizoma Panacis Japonici water extract low dose group, Rhizoma Panacis Japonici ethanol extract high dose group, Rhizoma Panacis Japonici ethanol extract low dose group and model group relatively all have utmost point significant difference (P＜0.01); After 14 days, after the 21st day, the high dose group of each administration all has utmost point significant difference (P＜0.01), and the low dose group of each administration all has significant difference (P＜0.05); And Chinese medicine positive drug TONGFENGDING Capsules group does not have significant difference.Show that panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, Rhizoma Panacis Japonici ethanol extract in the renal injury model that hyperuricemia causes, have the multiple injury of kidney effect that utmost point significance is repaiied, and Chinese medicine positive drug TONGFENGDING capsule do not have this effect.
(5) conclusion
Panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, Rhizoma Panacis Japonici ethanol extract have the utmost point significance effect that reduces animal pattern serum uric acid content.Show that panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, Rhizoma Panacis Japonici ethanol extract have the utmost point significance effect of repairing the injury of kidney that hyperuricemia causes.The main path that shows panax japonicus total saponins, Rhizoma Panacis Japonici saponin v, Rhizoma Panacis Japonici water extract, the effect of Rhizoma Panacis Japonici ethanol extract reduction animal pattern serum uric acid content realizes by reparation injury of kidney, increase kidney discharge capacity.
Embodiment 5
Get the Rhizoma Panacis Japonici medical material, the decocting that adds 6 times of amounts of Rhizoma Panacis Japonici boils 1 time, and decocting time is 3 hours, filters, and filtrate is concentrated into medical material: medicinal liquid be 1: 10 aqueous solution (0.1g crude drug/ml), promptly.
Embodiment 6
Get the Rhizoma Panacis Japonici medical material, the decocting that adds 12 times of amounts of Rhizoma Panacis Japonici boils 4 times, and decocting time was respectively 2 hours, filter, and merging filtrate, filtrate concentrates.Add granule adjuvant commonly used, preparation technology is prepared into granule routinely.
Embodiment 7
Get the Rhizoma Panacis Japonici coarse granule, place round-bottomed flask, add 90% methanol of 8 times of amounts of Rhizoma Panacis Japonici coarse granule, soaked 2 hours, water-bath reflux, extract, 2 hours filters, must filtrate.90% methanol eddy of 8 times of amounts of medicinal residues reuse extracts 1 time, extracts filtration 1 hour.Merge 2 times filtrate, reclaim under reduced pressure methanol is not to there being the alcohol flavor, and be mixed with medical material: medicinal liquid (0.1g/ml) is 1: 10 a aqueous solution.
Embodiment 8
Get the Rhizoma Panacis Japonici coarse granule, place round-bottomed flask, add 90% ethanol of 6 times of amounts of Rhizoma Panacis Japonici coarse granule, soaked 2 hours, water-bath reflux, extract, 3 hours filters, must filtrate.90% alcohol reflux of 6 times of amounts of medicinal residues reuse 3 times each 1 hour, filters.Merge 4 times filtrate, filtrate concentrates.Add capsule adjuvant commonly used, preparation technology is prepared into capsule routinely.
Embodiment 9
Get the Rhizoma Panacis Japonici coarse granule, place round-bottomed flask, add 10% methanol of 12 times of amounts of Rhizoma Panacis Japonici coarse granule, soaked 2 hours, water-bath reflux, extract, 2 hours filters, must filtrate.10% methanol eddy of 12 times of amounts of medicinal residues reuse extracts 3 times, extracts 1 hour at every turn, filters.Merge 4 times filtrate, concentrate.Add oral liquid adjuvant commonly used, preparation technology is prepared into oral liquid routinely.
Embodiment 10
Get the Rhizoma Panacis Japonici coarse granule, place round-bottomed flask, add 10% ethanol of 12 times of amounts of Rhizoma Panacis Japonici coarse granule, soaked 2 hours, water-bath reflux, extract, 1 hour filters, must filtrate.10% alcohol reflux of 12 times of amounts of medicinal residues reuse 1 time, each 1 hour, filter, merges 2 times filtrate, concentrated.Add tablet adjuvant commonly used, preparation technology is prepared into tablet routinely.
Claims (10)
1. Rhizoma Panacis Japonici or Rhizoma Panacis Japonici extract are as the application of active component in the medicine of preparation gout and/or reparation metabolic arthritis injury of kidney.
2. application according to claim 1 is characterized in that the refining Rhizoma Panacis Japonici extract that water extract that described Rhizoma Panacis Japonici extract is the water extract of Rhizoma Panacis Japonici, ethanol extract, Rhizoma Panacis Japonici or ethanol extract obtain after refining.
3. application according to claim 2 is characterized in that described refining Rhizoma Panacis Japonici extract is Rhizoma Panacis Japonici saponin ⅴ or panax japonicus total saponins.
4. application according to claim 3 is characterized in that content 〉=50% of Rhizoma Panacis Japonici saponin ⅴ in the described panax japonicus total saponins.
5. application according to claim 3 is characterized in that purity 〉=90% of described Rhizoma Panacis Japonici saponin ⅴ.
6. application according to claim 2 is characterized in that described ethanol extract is the extract of ethanol or methanol, and the concentration of ethanol or methanol is 10-90%.
7. application according to claim 6, the concentration that it is characterized in that described ethanol or methanol is 50-70%.
8. application according to claim 2 is characterized in that the water extract of described Rhizoma Panacis Japonici is prepared by following method: get the Rhizoma Panacis Japonici medical material, add the decocting that Rhizoma Panacis Japonici 6-12 doubly measures and boil 1-4 time, decocting time was respectively 1-3 hour, filtered merging filtrate, concentrate, promptly.
9. application according to claim 2 is characterized in that the ethanol extract of described Rhizoma Panacis Japonici is prepared by following method: get the Rhizoma Panacis Japonici medical material, ethanol or methanol eddy that adding Rhizoma Panacis Japonici 6-12 doubly measures extracted 1-3 hour, filtered, and got filtrate; Ethanol that medicinal residues reuse 6-12 doubly measures or methanol eddy extract 1-3 time, and each 1-3 hour, filter, merging filtrate concentrates, promptly.
10. a gout and repair the pharmaceutical composition of metabolic arthritis injury of kidney contains Rhizoma Panacis Japonici any among the claim 1-9 or its extract and pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105491374A CN101978982B (en) | 2010-11-17 | 2010-11-17 | Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105491374A CN101978982B (en) | 2010-11-17 | 2010-11-17 | Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101978982A true CN101978982A (en) | 2011-02-23 |
| CN101978982B CN101978982B (en) | 2012-11-28 |
Family
ID=43599537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105491374A Active CN101978982B (en) | 2010-11-17 | 2010-11-17 | Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101978982B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103301414A (en) * | 2013-07-05 | 2013-09-18 | 杨中林 | Medicine composition resisting gout, promoting renal excretion, and repairing renal injury, as well as preparation method and application for same |
| CN105168284A (en) * | 2015-09-09 | 2015-12-23 | 杨小林 | Application of panax japonicus saponins V and total panax japonicus saponins thereof to preparation of medicament for resisting urathritis |
| CN106420758A (en) * | 2016-08-31 | 2017-02-22 | 昆明理工大学 | Method for inducing mouse gout model through long-term hyperuricemia |
| CN106822205A (en) * | 2017-04-11 | 2017-06-13 | 中南民族大学 | Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247391A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Application of panax japonicus saponin V to reduction of blood fat |
| CN102247416A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Blood lipid lowering application of total saponins of panax japonicus |
-
2010
- 2010-11-17 CN CN2010105491374A patent/CN101978982B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247391A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Application of panax japonicus saponin V to reduction of blood fat |
| CN102247416A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Blood lipid lowering application of total saponins of panax japonicus |
Non-Patent Citations (4)
| Title |
|---|
| 《中国博士学位论文全文数据库医药卫生科技辑》 20091115 袁丁 竹节参药效物质及药材质量分析研究 第17-18页 8-10 , 第11期 * |
| 《国外药学·植物药分册》 19810829 Huh K等 在乙醇引起的血尿酸过高症中人参皂苷对黄嘌呤氧化酶活性的效应 第43-44页 1-3,6-10 , * |
| 《湖北民族学院学报·医学版》 20081231 陈龙全等 竹节参提取液抗风湿作用的实验研究 第15-17,21页 1-3,6-10 第25卷, 第3期 * |
| 李志明: "高尿酸血症病机探讨及固本化痰方对HUA小鼠模型UA及相关酶的影响", 《中国优秀博硕士学位论文全文数据库（硕士）医药卫生科技辑》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103301414A (en) * | 2013-07-05 | 2013-09-18 | 杨中林 | Medicine composition resisting gout, promoting renal excretion, and repairing renal injury, as well as preparation method and application for same |
| CN103301414B (en) * | 2013-07-05 | 2015-12-02 | 杨中林 | Gout, short kidney are arranged, repair kidney damages pharmaceutical composition and its preparation method and application |
| CN105168284A (en) * | 2015-09-09 | 2015-12-23 | 杨小林 | Application of panax japonicus saponins V and total panax japonicus saponins thereof to preparation of medicament for resisting urathritis |
| CN106420758A (en) * | 2016-08-31 | 2017-02-22 | 昆明理工大学 | Method for inducing mouse gout model through long-term hyperuricemia |
| CN106420758B (en) * | 2016-08-31 | 2018-09-11 | 昆明理工大学 | A method of utilizing long-term hyperuricemia inducing mouse Gout Model |
| CN106822205A (en) * | 2017-04-11 | 2017-06-13 | 中南民族大学 | Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101978982B (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101920002B (en) | Chinese medicinal formula for treating gout and hyperuricemia | |
| CN102727508A (en) | Preparation of panaxadiol saponins component and pharmaceutical application for prevention and treatment of Parkinson disease | |
| CN101978982B (en) | Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury | |
| CN105687994A (en) | Traditional Chinese medicine composition for treating chronic renal failure and preparation method thereof | |
| CN103585192B (en) | A kind of preparation method of Aleuritopteris argentea (Gmel.) Fee extract and application thereof | |
| CN105168284A (en) | Application of panax japonicus saponins V and total panax japonicus saponins thereof to preparation of medicament for resisting urathritis | |
| CN108743795B (en) | Korean medicine extract for preventing and treating diabetic nephropathy and preparation method and application thereof | |
| CN101850063A (en) | Medicinal preparation for preventing and treating gout and preparation method | |
| CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| CN102228666B (en) | Composition prepared from pine pollen and curcuma, preparation method thereof, and application of composition in preparing medicament for treating inflammatory bowel disease | |
| CN103705812B (en) | A kind of pharmaceutical composition for the treatment of gout and its production and use | |
| CN103751450A (en) | Composition for treating diabetic nephropathy | |
| CN103705772B (en) | Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof | |
| CN110064016B (en) | Traditional Chinese medicine composition for regulating immune state of chronic kidney disease and preparation method thereof | |
| CN106421523B (en) | A kind of Chinese medicine compound prescription for treating gout | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
| CN105169187B (en) | A kind of composition and its application, preparation method and drug, food containing the composition | |
| CN103751583A (en) | Traditional Chinese medicine composition for being diuretic and protecting liver and preparation method of composition | |
| CN101926848B (en) | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof | |
| CN113546116B (en) | Preparation method of traditional Chinese medicine extract with blood pressure lowering effect | |
| CN112717078B (en) | Traditional Chinese medicine composition, preparation thereof, preparation method and application | |
| CN105998453A (en) | Traditional Chinese medicine for treating gout and hyperuricemia | |
| CN101181349A (en) | Application of Salvia przewalskii Maxim extract in the preparation of medicament for curing nephritis of renal glomerulus | |
| CN105726624A (en) | Pharmaceutical composition for treating diabetes | |
| CN103705775B (en) | One protects the liver analgesia Chinese medicine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |